Strategic platform Pelican Expression Technology Platform offers robust, scalable protein production suitable for complex, large-scale manufacturing, presenting a compelling out-licensing and collaboration opportunity for biopharma developers seeking faster timelines and reduced production costs.

Recent investor activity Ligand Pharmaceuticals invested $15M into Pelican, signaling credibility and potential for strategic partnerships or co-development agreements that can open doors to licensing deals, equity-backed collaborations, or joint ventures.

Market alignment Growing demand for large and complex biologics positions Pelican as a favorable partner for developers facing limitations of traditional systems, offering a competitive edge for outsourced manufacturing and potential expansion into vaccine and therapeutic production programs.

Financial scale Current revenue in the lower mid-range (approximately $1M-$10M) with strong growth potential through out-licensing and multi-project engagements with mid to large biopharma players who require scalable protein production platforms.

Strategic partnerships Recent merger activity resulting in Primrose Bio alongside Pelican Technology Holdings creates pathways for coordinated sales motions, cross-promotion to a broader customer base, and joint go-to-market strategies with partners seeking scalable expression platforms.